NEW YORK (TheStreet) -- Alcobra (ADHD) shares are down -2.81% to $20.03 on Wednesday after having coverage initiated with a "market perform" rating and $23 price target by analysts at FBR Capital Markets.
The Israel-based biopharmaceutical company is in the process of developing a drug treatment for Attention Deficit Hyperactivity Disorder.
ADHD data by YCharts
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.